Metropolis Healt

Metropolis Healthcare Ltd Key Ratios

NSEBSE

₹1,701.5

(-0.19%)

Apr 30, 2025|03:57:27 PM

Invest wise with Expert advice

QUICKLINKS FOR Metropolis Healthcare Ltd

FINANCIALS

Profit & Loss Balance Sheet Cash Flow Ratios Results

ConsolidatedStandalone

GraphTable

Y/e 31 Mar	Mar-2022	Mar-2021	Mar-2020
Growth matrix (%)
Revenue growth	23.08	16.53
Op profit growth	19.85	22.84
EBIT growth	17.88	24.72
Net profit growth	16.97	43.8
Profitability ratios (%)
OPM	27.9	28.65	27.18
EBIT margin	24.19	25.26	23.6
Net profit margin	17.43	18.34	14.86
RoCE	26.95	35.26
RoNW	6.72	7.44
RoA	4.85	6.4
Per share ratios (₹)
EPS	41.95	35.87	25.19
Dividend per share	8	8	8
Cash EPS	29.5	26.83	17.39
Book value per share	173.17	138.23	103.39
Valuation ratios
P/E	48.55	62.47	51.06
P/CEPS	69.03	83.52	73.95
P/B	11.76	16.21	12.44
EV/EBIDTA	29.5	37.4	26.38
Payout (%)
Dividend payout	19.11	22.33	38
Tax payout	-28.35	-24.95	-21.25
Liquidity ratios
Debtor days	38.4	45.94
Inventory days	13.61	11.87
Creditor days	-45.78	-53.41
Leverage ratios
Interest coverage	-15.05	-32.39	-24.22
Net debt / equity	0.23	-0.43	-0.27
Net debt / op. profit	0.61	-1.07	-0.61
Cost breakup (₹)
Material costs	-22.47	-25.26	-23.83
Employee costs	-18.98	-19.9	-22.2
Other costs	-30.63	-26.17	-26.77

Metropolis Healt : related Articles

Metropolis Healthcare Q3 Profit Rises 15.4% to ₹31.4 Crore

6 Feb 2025|10:11 AM

The EBITDA margin was stable at 22.3% and did not change much from the year-ago period.

Metropolis Acquires Core Diagnostics for ₹247 Crore to Boost Cancer Testing Expertise

10 Dec 2024|04:16 PM

This is a 100% stake purchase that will be funded through 55% cash and 45% equity swap. It expects completion in 60 days, after shareholders give their nod.